- Home
- IMCR vs PINC Comparison
IMCR vs PINC Comparison
Compare IMCR & PINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PINC
- Stock Information
- Founded
- IMCR 2008
- PINC 2013
- Country
- IMCR United Kingdom
- PINC United States
- Employees
- IMCR N/A
- PINC N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PINC Other Consumer Services
- Sector
- IMCR Health Care
- PINC Consumer Discretionary
- Exchange
- IMCR Nasdaq
- PINC Nasdaq
- Market Cap
- IMCR 1.6B
- PINC 1.9B
- IPO Year
- IMCR 2021
- PINC 2013
- Fundamental
- Price
- IMCR $33.99
- PINC $21.68
- Analyst Decision
- IMCR Buy
- PINC Hold
- Analyst Count
- IMCR 10
- PINC 6
- Target Price
- IMCR $58.13
- PINC $22.20
- AVG Volume (30 Days)
- IMCR 422.6K
- PINC 2.4M
- Earning Date
- IMCR 08-07-2025
- PINC 08-19-2025
- Dividend Yield
- IMCR N/A
- PINC 3.83%
- EPS Growth
- IMCR N/A
- PINC N/A
- EPS
- IMCR N/A
- PINC 0.63
- Revenue
- IMCR $333,581,000.00
- PINC $1,260,388,000.00
- Revenue This Year
- IMCR $26.82
- PINC N/A
- Revenue Next Year
- IMCR $8.15
- PINC N/A
- P/E Ratio
- IMCR N/A
- PINC $34.61
- Revenue Growth
- IMCR 25.75
- PINC 7.16
- 52 Week Low
- IMCR $23.15
- PINC $17.23
- 52 Week High
- IMCR $41.54
- PINC $23.56
- Technical
- Relative Strength Index (RSI)
- IMCR 56.49
- PINC 42.11
- Support Level
- IMCR $32.20
- PINC $21.40
- Resistance Level
- IMCR $33.95
- PINC $22.24
- Average True Range (ATR)
- IMCR 1.22
- PINC 0.40
- MACD
- IMCR 0.06
- PINC -0.03
- Stochastic Oscillator
- IMCR 95.84
- PINC 32.50
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PINC Premier Inc.
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.